ConductScience.org, home

Paper39335671

Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.

Ghemrawi R and 7 others. Biomedicines, 2024. Cited by 66 papers, by iCite.

Cite this record

ConductScience Library. Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. Papers, record 39335671. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39335671

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy.
PubMed
Journal
Biomedicines
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
66
iCite
Relative citation ratio, by iCite
9.56, provisional
iCite
Revised in PubMed
2024-09-30
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ghemrawi RRosehttps://orcid.org/0000-0002-2465-0812
2Abuamer LLama
3Kremesh SSedrahttps://orcid.org/0000-0001-6480-4292
4Hussien GGhadeerhttps://orcid.org/0009-0003-6175-8501
5Ahmed RRahaf
6Mousa WWalaa
7Khoder GGhaliahttps://orcid.org/0000-0002-6036-1022
8Khair MMostafahttps://orcid.org/0000-0001-6555-0642

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References177

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137896162Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions.Pharmaceutics2023https://conductscience.org/library/papers/37896162PubMed
238139301Advances in Targeted Immunotherapy in Cancers.Int J Mol Sci2023https://conductscience.org/library/papers/38139301PubMed
329869168Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.Cancer Immunol Immunother2018https://conductscience.org/library/papers/29869168PubMed
421768293Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy.Blood2011https://conductscience.org/library/papers/21768293PubMed
518073223Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells.Protein Eng Des Sel2008https://conductscience.org/library/papers/18073223PubMed
627435312A short CD3/CD28 costimulation combined with IL-21 enhance the generation of human memory stem T cells for adoptive immunotherapy.J Transl Med2016https://conductscience.org/library/papers/27435312PubMed
733802331Recent Advancements on Immunomodulatory Mechanisms of Resveratrol in Tumor Microenvironment.Molecules2021https://conductscience.org/library/papers/33802331PubMed
811825563Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength.Immunity2002https://conductscience.org/library/papers/11825563PubMed
932698317Monoclonal Antibodies in Cancer Therapy.Antibodies (Basel)2020https://conductscience.org/library/papers/32698317PubMed
1035794202A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.Commun Biol2022https://conductscience.org/library/papers/35794202PubMed
1116155579Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms.Nat Med2005https://conductscience.org/library/papers/16155579PubMed
1230214153A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities.Drug Des Devel Ther2018https://conductscience.org/library/papers/30214153PubMed
1338149884Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies.Immunohorizons2023https://conductscience.org/library/papers/38149884PubMed
1429462558Molecular Imaging of Mesothelin-Expressing Ovarian Cancer with a Human and Mouse Cross-Reactive Nanobody.Mol Pharm2018https://conductscience.org/library/papers/29462558PubMed
1528029927Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.N Engl J Med2016https://conductscience.org/library/papers/28029927PubMed
1637681891Cancer Vaccine Therapeutics: Limitations and Effectiveness-A Literature Review.Cells2023https://conductscience.org/library/papers/37681891PubMed
1731921205The Intriguing History of Cancer Immunotherapy.Front Immunol2019https://conductscience.org/library/papers/31921205PubMed
1825632005A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells.J Immunol2015https://conductscience.org/library/papers/25632005PubMed
1931894001Development of therapeutic antibodies for the treatment of diseases.J Biomed Sci2020https://conductscience.org/library/papers/31894001PubMed
2035392964Cancer combination therapies by angiogenesis inhibitors; a comprehensive review.Cell Commun Signal2022https://conductscience.org/library/papers/35392964PubMed

See all 177 referencesDownload CSV of references

Cited by53

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 66 citations.

PMIDTitleJournalYearIn PapersSource
42920849Progress on therapeutic mRNA vaccines for cancer.Front Oncol2026https://conductscience.org/library/papers/42920849PubMed
42840090Immune checkpoint inhibitor-related myotoxicity in lung cancer: a decade-long real-world pharmacovigilance analysis of the FAERS database.Front Pharmacol2026https://conductscience.org/library/papers/42840090PubMed
42814277Recent advancements and persisting challenges in the evolution of next generation car t cell therapy for solid malignancies: a comprehensive review.Immunol Res2026https://conductscience.org/library/papers/42814277PubMed
42797543Engineering Functional Biomaterials for Targeted and Localized Cancer Drug Delivery: A Structure-Property-Performance Design Perspective.Pharmaceuticals (Basel)2026https://conductscience.org/library/papers/42797543PubMed
42749398mRNA-based therapeutics in lung Cancer: Mechanisms, applications, and translational challenges.J Genet Eng Biotechnol2026https://conductscience.org/library/papers/42749398PubMed
42689115The Cancer Epitope Database and Analysis Resource (CEDAR): current capabilities and future directions.Front Oncol2026https://conductscience.org/library/papers/42689115PubMed
42677342Integrating AI, RNA Vaccines, and CAR-T Cells for Personalized Treatment.J Immunol Res2026https://conductscience.org/library/papers/42677342PubMed
42624898Advanced gene editing technologies for oncology mechanisms, applications, and clinical implementation.Cancer Gene Ther2026https://conductscience.org/library/papers/42624898PubMed
42559290Antibody-Drug Conjugates and Peptide-Drug Conjugates: Current Understandings and Future Perspectives.MedComm (2020)2026https://conductscience.org/library/papers/42559290PubMed
42380303Integrating artificial intelligence into small molecule development for precision cancer immunomodulation therapy.NPJ Drug Discov2025https://conductscience.org/library/papers/42380303PubMed
42338900Glucan-Based Nanoparticles Empower Precision Cancer Immunotherapy: Design Strategies, Immune Reprogramming Mechanisms, and Clinical Translation Prospects.Int J Nanomedicine2026https://conductscience.org/library/papers/42338900PubMed
42243936Clinical application of cytokine-induced killer cells in cancer immunotherapy.Cancer Cell Int2026https://conductscience.org/library/papers/42243936PubMed
42237149Immunoinformatics-guided design of a multi-epitope vaccine targeting WISP1 for gastric cancer.BMC Biotechnol2026https://conductscience.org/library/papers/42237149PubMed
42191970Production of monoclonal antibodies (mAbs) against oralcarcinoma & its bioconjugation with solid lipid nanoparticles (SLN) for drug delivery.Discov Oncol2026https://conductscience.org/library/papers/42191970PubMed
41971016Role of circular RNAs in regulating toxicity induced by cancer therapies.Genes Dis2026https://conductscience.org/library/papers/41971016PubMed
41933234Emerging nanoimmunotherapeutic strategies for breast cancer.Discov Oncol2026https://conductscience.org/library/papers/41933234PubMed
41870184The Trifecta of Polo-Like Kinases, Cancer, and the Immune System: Emerging Intersections and Therapeutic Insights.Mol Cancer Res2026https://conductscience.org/library/papers/41870184PubMed
41836358Crosstalk between autophagy and apoptosis in initiating antitumor immune responses in human lymphoma cells.Explor Immunol2025https://conductscience.org/library/papers/41836358PubMed
41657772Natural compounds in ovarian cancer: mechanistic insights and therapeutic potential.Front Pharmacol2025https://conductscience.org/library/papers/41657772PubMed
41634702The molecular mechanism of IGF2BP3 promoting the malignant progression of lung cancer.Cancer Cell Int2026https://conductscience.org/library/papers/41634702PubMed

See all 53 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
NR1I39970PubTator's text mininghttps://conductscience.org/library/genes/9970

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39335671

GET https://conductscience.org/api/papers/v1/39335671/references?page=2